Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06178146
Status:
RECRUITING
Last Update Posted:
2023-12-20
First Post:
2023-12-03
Brief Title:
Thymosin Alpha-1 for irAE Secondary to ICIs
Sponsor:
Jun Wang
Organization:
Qianfoshan Hospital
Study Overview
Official Title:
A Prospective Open Randomized Controlled Stage II Trial Investigating the Efficacy and Safety of Thymosin Alpha-1 in Treating Moderate to Severe Immune-related Adverse Events
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Thymosin alpha-1 Tα-1 has shown clinical benefits in patients whose immune functions are severely compromised or ineffective Therefore this study is attempted to explore whether Tα-1 could be used as a therapeutic option for the treatment of immune-related adverse events irAEs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None